- Conditions
- Primary Biliary Cholangitis
- Interventions
- Mindfulness Based Intervention
- Behavioral
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 97–120
of 197
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Liver Diseases, Alagille Syndrome, Alpha 1-Antitrypsin Deficiency
- Interventions
- Not listed
- Lead sponsor
- Arbor Research Collaborative for Health
- Other
- Eligibility
- Up to 25 Years
- Enrollment
- 1,675 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2029
- U.S. locations
- 16
- States / cities
- Los Angeles, California • San Francisco, California • Aurora, Colorado + 12 more
- Conditions
- Primary Sclerosing Cholangitis
- Interventions
- Oral Vancomycin
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 1 Year and older
- Enrollment
- 34 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Parenteral Nutrition Associated Liver Disease
- Interventions
- Omegaven
- Drug
- Lead sponsor
- St. Luke's Health System, Boise, Idaho
- Other
- Eligibility
- Up to 17 Years
- U.S. locations
- 1
- States / cities
- Boise, Idaho
- Conditions
- Short Bowel Syndrome, Cholestasis
- Interventions
- Omegaven Therapy
- Drug
- Lead sponsor
- Amarnath, Rathna, M.D.
- Individual
- Eligibility
- Up to 1 Year
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Columbia, South Carolina
- Conditions
- Cholestasis, Liver Disease
- Interventions
- Enteral fish oil, Ursodeoxycholic Acid, Placebo
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 14 Days to 24 Months
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer, Pancreatic Cancer
- Interventions
- porfimer sodium
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2002
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Pruritus
- Interventions
- EP547, Placebo
- Drug
- Lead sponsor
- Escient Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Coronado, California + 17 more
- Conditions
- Primary Biliary Cirrhosis
- Interventions
- Obeticholic Acid
- Drug
- Lead sponsor
- Intercept Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 7
- States / cities
- La Jolla, California • Sacramento, California • Miami, Florida + 4 more
- Conditions
- Liver Cirrhosis, Biliary
- Interventions
- Placebo, Obeticholic Acid (OCA)
- Drug
- Lead sponsor
- Intercept Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2017
- U.S. locations
- 4
- States / cities
- Detroit, Michigan • Houston, Texas • Richmond, Virginia + 1 more
- Conditions
- Primary Biliary Cholangitis, PBC
- Interventions
- Volixibat, Placebo
- Drug
- Lead sponsor
- Mirum Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 333 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 44
- States / cities
- Coronado, California • Los Angeles, California • Sacramento, California + 38 more
- Conditions
- Biliary Stricture
- Interventions
- Temperature-sensitive radiofrequency ablation, No intervention
- Procedure · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 176 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Cholangitis, Secondary Biliary, Cholangiocarcinoma, Obstructive Jaundice, Pancreas Cancer, COVID-19, SARS-CoV-2
- Interventions
- Endoscopic management according to standard of care
- Other
- Lead sponsor
- Al-Azhar University
- Other
- Eligibility
- Not listed
- Enrollment
- 670 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Albertson, New York
- Conditions
- Cystic Fibrosis, Gastrointestinal Diseases, Cholestasis
- Interventions
- ursodiol
- Drug
- Lead sponsor
- National Center for Research Resources (NCRR)
- NIH
- Eligibility
- 4 Months and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1995
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Primary Biliary Cholangitis
- Interventions
- Bezafibrate 100 mg, Bezafibrate 200 mg, Obeticholic Acid 5 mg, Obeticholic Acid placebo, Bezafibrate Placebo
- Drug
- Lead sponsor
- Intercept Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Coronado, California • Mission Hills, California + 14 more
- Conditions
- Chronic Hepatic Pruritus, Cholestatic Liver Disease, Primary Biliary Cholangitis, Cholestasis, Primary Sclerosing Cholangitis
- Interventions
- Nemolizumab-ilto
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Cholestasis, Total Parenteral Nutrition-induced Cholestasis
- Interventions
- Omegaven
- Drug
- Lead sponsor
- Cindy Haller
- Other
- Eligibility
- 2 Weeks to 5 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 2
- States / cities
- Manhasset, New York • New Hyde Park, New York
- Conditions
- Primary Biliary Cholangitis
- Interventions
- Not listed
- Lead sponsor
- Ipsen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 3
- States / cities
- Chandler, Arizona • Miami, Florida • Dallas, Texas
- Conditions
- Fatigue, Primary Biliary Cirrhosis
- Interventions
- Modafinil
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 21 Years to 75 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Primary Biliary Cholangitis
- Interventions
- Part 1: LJN452, Part 1: Placebo, Part 2: LJN452 Dose level 1, Part 2: Placebo, Part 2: LJN452 Dose level 2
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 9
- States / cities
- Rialto, California • Miami, Florida • Atlanta, Georgia + 6 more
- Conditions
- Intrahepatic Cholestasis of Pregnancy
- Interventions
- Volixibat, Placebo
- Drug
- Lead sponsor
- Mirum Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • New Haven, Connecticut • Miami, Florida + 4 more
- Conditions
- Liver Failure, Liver Diseases, Alcoholic, Liver Diseases, Pain, Postoperative, Transplant; Failure, Liver, Liver Cirrhosis, Biliary
- Interventions
- BRIDGE device
- Device
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Total Parenteral Nutrition-Induced Cholestasis
- Interventions
- Omegaven
- Drug
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- Up to 18 Years
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Intestinal Failure-associated Liver Disease
- Interventions
- Not listed
- Lead sponsor
- Protara Therapeutics
- Industry
- Eligibility
- 12 Years to 80 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Kissimmee, Florida • Chicago, Illinois + 7 more